SlideShare ist ein Scribd-Unternehmen logo
1 von 52
Positioning DETROL (Creating a Disease) Neil Wolf Group Vice President, PHARMACIA Presented to PMRG October 7, 2002
Detrol Commercial
Positioning DETROL (Creating a Disease) Neil Wolf Group Vice President, PHARMACIA Presented to PMRG October 7, 2002
Pharmacia & Upjohn The Situation in 1995 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Pharmacia & Upjohn The Situation in 1997 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Detrol “Detrusitol” Status ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Detrol “Detrusitol” Status ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Market Dynamics ,[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Market Dynamics
Coping Mechanisms ,[object Object],[object Object]
Objective: Broaden and Own the Understanding of the Market ,[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Objective: Broaden and Own the Understanding of the Market
Converting a Niche Product into a   Mass Market Opportunity ,[object Object],[object Object],[object Object]
Converting a Niche Product into a   Mass Market Opportunity ,[object Object],[object Object],[object Object],[object Object]
Converting a Niche Product into a   Mass Market Opportunity ,[object Object],[object Object]
Converting a Niche Product into a   Mass Market Opportunity ,[object Object],[object Object],[object Object]
Urge Incontinence Market US Urge Incontinence 12 million Sufferers
Overactive Bladder US Urge Incontinence 12 million sufferers Urgency Frequency  21 million sufferers 64% of patients suffer from “dry” OAB OAB is 2.7-fold larger opportunity than urge incontinence
OAB Definitions ,[object Object],[object Object],[object Object]
Critical Success Factors ,[object Object],[object Object],[object Object],[object Object]
Detrol Message ,[object Object],[object Object]
Detrol Message ,[object Object],[object Object],[object Object],[object Object],[object Object]
Detrol Message ,[object Object],[object Object],[object Object],[object Object],[object Object]
Detrol Strategic Imperatives CONVERSION Convert Pharmacological Therapy EXPANSION Patients identify with symptoms and seek treatment GROWTH PCPs “own” OAB
Detrol Strategies ,[object Object],[object Object],[object Object],[object Object],[object Object]
Detrol Strategies ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Detrol Strategies ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Creating OAB KOL’s Regulators OAB Sufferers Media Payors Prescribers
Creating OAB KOLs ,[object Object],[object Object],[object Object]
Changing the Playing Field ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Changing the Playing Field ,[object Object],[object Object]
Creating OAB Regulators ,[object Object],[object Object]
Creating OAB Regulators ,[object Object],[object Object],[object Object],[object Object]
Creating OAB Prescribers ,[object Object],[object Object],[object Object]
OAB Screen, Diagnose, Treat ,[object Object],[object Object],[object Object],[object Object],[object Object]
Creating OAB Payors ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Creating OAB Media
Launch Sequencing ,[object Object],[object Object],[object Object],[object Object],[object Object]
Summary ,[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],Differentiate from oxybutinin
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Differentiate from oxybutinin
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Differentiate from oxybutinin
Results! ,[object Object],[object Object],[object Object],[object Object]
Results! ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Results! ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Results! ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Results! ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Results! ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Estimated 2002 >$600M
 

Weitere ähnliche Inhalte

Ähnlich wie Detrol

ARDS: An Evidence-based Update. By Mac Sweeney.
ARDS: An Evidence-based Update. By Mac Sweeney.ARDS: An Evidence-based Update. By Mac Sweeney.
ARDS: An Evidence-based Update. By Mac Sweeney.SMACC Conference
 
Development Challenges Facing Big Pharma and the Industrial Pharmacist
Development Challenges Facing Big Pharma and the Industrial PharmacistDevelopment Challenges Facing Big Pharma and the Industrial Pharmacist
Development Challenges Facing Big Pharma and the Industrial PharmacistEuropean Industrial Pharmacists Group
 
Nestlé Health Science in the USA
Nestlé Health Science in the USANestlé Health Science in the USA
Nestlé Health Science in the USANestlé SA
 
ROJoson PEP Talk: CAN ONE SKIP RADIOACTIVE IODINE THERAPY IN THYROID CANCER T...
ROJoson PEP Talk: CAN ONE SKIP RADIOACTIVE IODINE THERAPY IN THYROID CANCER T...ROJoson PEP Talk: CAN ONE SKIP RADIOACTIVE IODINE THERAPY IN THYROID CANCER T...
ROJoson PEP Talk: CAN ONE SKIP RADIOACTIVE IODINE THERAPY IN THYROID CANCER T...Reynaldo Joson
 
ROJoson PEP Talk: Can one skip RADIOACTIVE IODINE THERAPY in Thyroid Cancer T...
ROJoson PEP Talk: Can one skip RADIOACTIVE IODINE THERAPY in Thyroid Cancer T...ROJoson PEP Talk: Can one skip RADIOACTIVE IODINE THERAPY in Thyroid Cancer T...
ROJoson PEP Talk: Can one skip RADIOACTIVE IODINE THERAPY in Thyroid Cancer T...Reynaldo Joson
 
Pharmanex Antioxidant Scanner
Pharmanex Antioxidant ScannerPharmanex Antioxidant Scanner
Pharmanex Antioxidant ScannerBill Muth
 
BioEntrepreneurship: Effective Communications - Selling your story
BioEntrepreneurship: Effective Communications - Selling your storyBioEntrepreneurship: Effective Communications - Selling your story
BioEntrepreneurship: Effective Communications - Selling your storyMaRS Discovery District
 
ARDS - An Evidence Based Update by Rob Mac Sweeney
ARDS -    An Evidence Based Update by Rob Mac SweeneyARDS -    An Evidence Based Update by Rob Mac Sweeney
ARDS - An Evidence Based Update by Rob Mac Sweeneyrobmacsweeney
 
Hand Held Nitrous Pitch Deck
Hand Held Nitrous Pitch DeckHand Held Nitrous Pitch Deck
Hand Held Nitrous Pitch Deckhandheldnitrous
 
Bio Derm Press Kit
Bio Derm Press KitBio Derm Press Kit
Bio Derm Press KitAmy Coelho
 
M100700053 shivani kakria
M100700053 shivani kakriaM100700053 shivani kakria
M100700053 shivani kakriashivanikakria
 
M100700053 shivani kakria
M100700053 shivani kakriaM100700053 shivani kakria
M100700053 shivani kakriashivanikakria
 
HIV Lipoatrophy 2007
HIV Lipoatrophy 2007HIV Lipoatrophy 2007
HIV Lipoatrophy 2007VHCONCEPTS
 
Connecting the Dots for Rare Disease Studies
Connecting the Dots for Rare Disease StudiesConnecting the Dots for Rare Disease Studies
Connecting the Dots for Rare Disease StudiesMedpace
 
Medical management of postpartum hemorrhage pph lecture
Medical management of postpartum hemorrhage pph lectureMedical management of postpartum hemorrhage pph lecture
Medical management of postpartum hemorrhage pph lectureChukwuma Onyeije, MD, FACOG
 
EuroBioForum2014_speaker_Love
EuroBioForum2014_speaker_LoveEuroBioForum2014_speaker_Love
EuroBioForum2014_speaker_LoveEuroBioForum
 
The four phases of intravenous fluid therapy: Manu Malbrain
The four phases of intravenous fluid therapy: Manu MalbrainThe four phases of intravenous fluid therapy: Manu Malbrain
The four phases of intravenous fluid therapy: Manu MalbrainSMACC Conference
 

Ähnlich wie Detrol (20)

ARDS: An Evidence-based Update. By Mac Sweeney.
ARDS: An Evidence-based Update. By Mac Sweeney.ARDS: An Evidence-based Update. By Mac Sweeney.
ARDS: An Evidence-based Update. By Mac Sweeney.
 
Development Challenges Facing Big Pharma and the Industrial Pharmacist
Development Challenges Facing Big Pharma and the Industrial PharmacistDevelopment Challenges Facing Big Pharma and the Industrial Pharmacist
Development Challenges Facing Big Pharma and the Industrial Pharmacist
 
Launch of a new Pharmaceutical Product
Launch of a new Pharmaceutical ProductLaunch of a new Pharmaceutical Product
Launch of a new Pharmaceutical Product
 
Nestlé Health Science in the USA
Nestlé Health Science in the USANestlé Health Science in the USA
Nestlé Health Science in the USA
 
ROJoson PEP Talk: CAN ONE SKIP RADIOACTIVE IODINE THERAPY IN THYROID CANCER T...
ROJoson PEP Talk: CAN ONE SKIP RADIOACTIVE IODINE THERAPY IN THYROID CANCER T...ROJoson PEP Talk: CAN ONE SKIP RADIOACTIVE IODINE THERAPY IN THYROID CANCER T...
ROJoson PEP Talk: CAN ONE SKIP RADIOACTIVE IODINE THERAPY IN THYROID CANCER T...
 
ROJoson PEP Talk: Can one skip RADIOACTIVE IODINE THERAPY in Thyroid Cancer T...
ROJoson PEP Talk: Can one skip RADIOACTIVE IODINE THERAPY in Thyroid Cancer T...ROJoson PEP Talk: Can one skip RADIOACTIVE IODINE THERAPY in Thyroid Cancer T...
ROJoson PEP Talk: Can one skip RADIOACTIVE IODINE THERAPY in Thyroid Cancer T...
 
Pharmanex Antioxidant Scanner
Pharmanex Antioxidant ScannerPharmanex Antioxidant Scanner
Pharmanex Antioxidant Scanner
 
The cost of doing nothing
The cost of doing nothing The cost of doing nothing
The cost of doing nothing
 
BioEntrepreneurship: Effective Communications - Selling your story
BioEntrepreneurship: Effective Communications - Selling your storyBioEntrepreneurship: Effective Communications - Selling your story
BioEntrepreneurship: Effective Communications - Selling your story
 
ARDS - An Evidence Based Update by Rob Mac Sweeney
ARDS -    An Evidence Based Update by Rob Mac SweeneyARDS -    An Evidence Based Update by Rob Mac Sweeney
ARDS - An Evidence Based Update by Rob Mac Sweeney
 
Hand Held Nitrous Pitch Deck
Hand Held Nitrous Pitch DeckHand Held Nitrous Pitch Deck
Hand Held Nitrous Pitch Deck
 
Bio Derm Press Kit
Bio Derm Press KitBio Derm Press Kit
Bio Derm Press Kit
 
M100700053 shivani kakria
M100700053 shivani kakriaM100700053 shivani kakria
M100700053 shivani kakria
 
M100700053 shivani kakria
M100700053 shivani kakriaM100700053 shivani kakria
M100700053 shivani kakria
 
HIV Lipoatrophy 2007
HIV Lipoatrophy 2007HIV Lipoatrophy 2007
HIV Lipoatrophy 2007
 
Connecting the Dots for Rare Disease Studies
Connecting the Dots for Rare Disease StudiesConnecting the Dots for Rare Disease Studies
Connecting the Dots for Rare Disease Studies
 
Medical management of postpartum hemorrhage pph lecture
Medical management of postpartum hemorrhage pph lectureMedical management of postpartum hemorrhage pph lecture
Medical management of postpartum hemorrhage pph lecture
 
Obesity Back To Basics 2011
Obesity Back To Basics 2011Obesity Back To Basics 2011
Obesity Back To Basics 2011
 
EuroBioForum2014_speaker_Love
EuroBioForum2014_speaker_LoveEuroBioForum2014_speaker_Love
EuroBioForum2014_speaker_Love
 
The four phases of intravenous fluid therapy: Manu Malbrain
The four phases of intravenous fluid therapy: Manu MalbrainThe four phases of intravenous fluid therapy: Manu Malbrain
The four phases of intravenous fluid therapy: Manu Malbrain
 

Mehr von PHARMACOSERÍAS

Mesa Sanidad Participativa Experiencias
Mesa Sanidad Participativa ExperienciasMesa Sanidad Participativa Experiencias
Mesa Sanidad Participativa ExperienciasPHARMACOSERÍAS
 
"Fake news: Gravedad severa"
"Fake news: Gravedad  severa""Fake news: Gravedad  severa"
"Fake news: Gravedad severa"PHARMACOSERÍAS
 
Mesa Redonda: Cómo dar de comer a una población de 9 mil millones en el 2050...
Mesa Redonda: Cómo dar de comer a una población  de 9 mil millones en el 2050...Mesa Redonda: Cómo dar de comer a una población  de 9 mil millones en el 2050...
Mesa Redonda: Cómo dar de comer a una población de 9 mil millones en el 2050...PHARMACOSERÍAS
 
Seminario ANIS/Pfizer para periodistas: Vacunas y medios de comunicacion
Seminario ANIS/Pfizer para periodistas: Vacunas y medios de comunicacionSeminario ANIS/Pfizer para periodistas: Vacunas y medios de comunicacion
Seminario ANIS/Pfizer para periodistas: Vacunas y medios de comunicacionPHARMACOSERÍAS
 
Kurere Club Presnsa Asturiana LNE
Kurere Club Presnsa Asturiana LNEKurere Club Presnsa Asturiana LNE
Kurere Club Presnsa Asturiana LNEPHARMACOSERÍAS
 
Infoxicación, Bulos y Fake News
Infoxicación, Bulos y Fake NewsInfoxicación, Bulos y Fake News
Infoxicación, Bulos y Fake NewsPHARMACOSERÍAS
 
Informar en Salud: Bulos, Estafas y Trolls
Informar en Salud: Bulos, Estafas y TrollsInformar en Salud: Bulos, Estafas y Trolls
Informar en Salud: Bulos, Estafas y TrollsPHARMACOSERÍAS
 
Mesa torre de babel / Factor Humano y Salud Grandes Enigmas de nuestro tiempo
Mesa torre de babel / Factor Humano y Salud Grandes Enigmas de nuestro tiempoMesa torre de babel / Factor Humano y Salud Grandes Enigmas de nuestro tiempo
Mesa torre de babel / Factor Humano y Salud Grandes Enigmas de nuestro tiempoPHARMACOSERÍAS
 
Moderador Mesa Instituto Roche/ANIS: Seminario de actualización en Investigac...
Moderador Mesa Instituto Roche/ANIS: Seminario de actualización en Investigac...Moderador Mesa Instituto Roche/ANIS: Seminario de actualización en Investigac...
Moderador Mesa Instituto Roche/ANIS: Seminario de actualización en Investigac...PHARMACOSERÍAS
 
Vicepresidente ANIS/Editor PHARMACOSERÍAS
Vicepresidente ANIS/Editor PHARMACOSERÍASVicepresidente ANIS/Editor PHARMACOSERÍAS
Vicepresidente ANIS/Editor PHARMACOSERÍASPHARMACOSERÍAS
 
LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarro...
LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarro...LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarro...
LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarro...PHARMACOSERÍAS
 
LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarro...
LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarro...LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarro...
LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarro...PHARMACOSERÍAS
 
Hª Blogosfera Sanitaria en España
Hª Blogosfera Sanitaria en EspañaHª Blogosfera Sanitaria en España
Hª Blogosfera Sanitaria en EspañaPHARMACOSERÍAS
 
"La Salud un manantial de risas"
"La Salud un manantial de risas""La Salud un manantial de risas"
"La Salud un manantial de risas"PHARMACOSERÍAS
 
Mesa:Sobre_VIVIR con cáncer
Mesa:Sobre_VIVIR con cáncerMesa:Sobre_VIVIR con cáncer
Mesa:Sobre_VIVIR con cáncerPHARMACOSERÍAS
 
Vivimos realmente la era del e-paciente empoderado?
Vivimos realmente la era del e-paciente empoderado?Vivimos realmente la era del e-paciente empoderado?
Vivimos realmente la era del e-paciente empoderado?PHARMACOSERÍAS
 
Internet para la salud, un "remedio"...?
Internet para la salud, un "remedio"...?Internet para la salud, un "remedio"...?
Internet para la salud, un "remedio"...?PHARMACOSERÍAS
 
3 Patas para un banco / II CBS
3 Patas para un banco / II CBS 3 Patas para un banco / II CBS
3 Patas para un banco / II CBS PHARMACOSERÍAS
 
Blogosfera Sanitaria Campus Gutenberg
Blogosfera Sanitaria Campus GutenbergBlogosfera Sanitaria Campus Gutenberg
Blogosfera Sanitaria Campus GutenbergPHARMACOSERÍAS
 

Mehr von PHARMACOSERÍAS (20)

Mesa Sanidad Participativa Experiencias
Mesa Sanidad Participativa ExperienciasMesa Sanidad Participativa Experiencias
Mesa Sanidad Participativa Experiencias
 
"Fake news: Gravedad severa"
"Fake news: Gravedad  severa""Fake news: Gravedad  severa"
"Fake news: Gravedad severa"
 
Mesa Redonda: Cómo dar de comer a una población de 9 mil millones en el 2050...
Mesa Redonda: Cómo dar de comer a una población  de 9 mil millones en el 2050...Mesa Redonda: Cómo dar de comer a una población  de 9 mil millones en el 2050...
Mesa Redonda: Cómo dar de comer a una población de 9 mil millones en el 2050...
 
Seminario ANIS/Pfizer para periodistas: Vacunas y medios de comunicacion
Seminario ANIS/Pfizer para periodistas: Vacunas y medios de comunicacionSeminario ANIS/Pfizer para periodistas: Vacunas y medios de comunicacion
Seminario ANIS/Pfizer para periodistas: Vacunas y medios de comunicacion
 
Kurere Club Presnsa Asturiana LNE
Kurere Club Presnsa Asturiana LNEKurere Club Presnsa Asturiana LNE
Kurere Club Presnsa Asturiana LNE
 
Infoxicación, Bulos y Fake News
Infoxicación, Bulos y Fake NewsInfoxicación, Bulos y Fake News
Infoxicación, Bulos y Fake News
 
Informar en Salud: Bulos, Estafas y Trolls
Informar en Salud: Bulos, Estafas y TrollsInformar en Salud: Bulos, Estafas y Trolls
Informar en Salud: Bulos, Estafas y Trolls
 
Mesa torre de babel / Factor Humano y Salud Grandes Enigmas de nuestro tiempo
Mesa torre de babel / Factor Humano y Salud Grandes Enigmas de nuestro tiempoMesa torre de babel / Factor Humano y Salud Grandes Enigmas de nuestro tiempo
Mesa torre de babel / Factor Humano y Salud Grandes Enigmas de nuestro tiempo
 
Moderador Mesa Instituto Roche/ANIS: Seminario de actualización en Investigac...
Moderador Mesa Instituto Roche/ANIS: Seminario de actualización en Investigac...Moderador Mesa Instituto Roche/ANIS: Seminario de actualización en Investigac...
Moderador Mesa Instituto Roche/ANIS: Seminario de actualización en Investigac...
 
Vicepresidente ANIS/Editor PHARMACOSERÍAS
Vicepresidente ANIS/Editor PHARMACOSERÍASVicepresidente ANIS/Editor PHARMACOSERÍAS
Vicepresidente ANIS/Editor PHARMACOSERÍAS
 
LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarro...
LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarro...LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarro...
LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarro...
 
LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarro...
LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarro...LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarro...
LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarro...
 
Hª Blogosfera Sanitaria en España
Hª Blogosfera Sanitaria en EspañaHª Blogosfera Sanitaria en España
Hª Blogosfera Sanitaria en España
 
"La Salud un manantial de risas"
"La Salud un manantial de risas""La Salud un manantial de risas"
"La Salud un manantial de risas"
 
Mesa:Sobre_VIVIR con cáncer
Mesa:Sobre_VIVIR con cáncerMesa:Sobre_VIVIR con cáncer
Mesa:Sobre_VIVIR con cáncer
 
Vivimos realmente la era del e-paciente empoderado?
Vivimos realmente la era del e-paciente empoderado?Vivimos realmente la era del e-paciente empoderado?
Vivimos realmente la era del e-paciente empoderado?
 
Por qué aquí...ANIS
Por qué aquí...ANISPor qué aquí...ANIS
Por qué aquí...ANIS
 
Internet para la salud, un "remedio"...?
Internet para la salud, un "remedio"...?Internet para la salud, un "remedio"...?
Internet para la salud, un "remedio"...?
 
3 Patas para un banco / II CBS
3 Patas para un banco / II CBS 3 Patas para un banco / II CBS
3 Patas para un banco / II CBS
 
Blogosfera Sanitaria Campus Gutenberg
Blogosfera Sanitaria Campus GutenbergBlogosfera Sanitaria Campus Gutenberg
Blogosfera Sanitaria Campus Gutenberg
 

Detrol

Hinweis der Redaktion

  1. How many have seen How many have heard of overactive bladder? How many have overactive bladder??? Overactive Bladder now a lexicon in American culture -cocktail parties / media / sitcoms / talk shows Most importantly, routinely discussed between patients and their physicians Not the case 4 years ago Pharmacia instrumental in creating new disease -improving lives of millions around world Over next 30 minutes, insights Many dedicated folks -as team leader, I get privledge -introduce you to our US Director for Detrol
  2. How many have seen How many have heard of overactive bladder? How many have overactive bladder??? Overactive Bladder now a lexicon in American culture -cocktail parties / media / sitcoms / talk shows Most importantly, routinely discussed between patients and their physicians Not the case 4 years ago Pharmacia instrumental in creating new disease -improving lives of millions around world Over next 30 minutes, insights Many dedicated folks -as team leader, I get privledge -introduce you to our US Director for Detrol
  3. Here you see our US Director hard at work in his company issued Detrol office I know you can’t read his screen…… close up
  4. This is the screen that our Detrol team sees when they log on each morning ------------------------------------------------------------------------------ Perspective of environment at time Company called P&U Historical perspective helps define motivation for Identifying Resourcing Executing the launch of Detrol
  5. Merged in 1995 Failed merger No integration Separate companies, separate locations, and separate priorities Lack of focus and leadership Downward spiral in sales and earnings…. And stock price
  6. Largest competition--- non action 2 nd largest competition-- pads